Cluster headache therapies: pharmacology and mode of action
| Autor: | Uwe Reuter, Jasper Mecklenburg, Margarita Sanchez del Rio |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
business.industry
Calcitonin Gene-Related Peptide Cluster headache Pain Treatment options Cluster Headache General Medicine medicine.disease Bioinformatics Disease cluster 030226 pharmacology & pharmacy Antibodies 03 medical and health sciences 0302 clinical medicine Drug Development 030220 oncology & carcinogenesis medicine Animals Humans Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics business Trigeminal autonomic cephalalgia Mode of action |
| Zdroj: | Expert Review of Clinical Pharmacology. 13:641-654 |
| ISSN: | 1751-2441 1751-2433 |
| DOI: | 10.1080/17512433.2020.1774361 |
| Popis: | Cluster headache (CH) is the most common trigeminal autonomic cephalalgia with a significant need for novel treatment options. While the use of most of the acute CH medications is supported by clinical trials and based on a pathophysiological concept for the generation of pain, the scientific evidence for preventive CH medications is very limited.This article reviews acute and preventive substances for the pharmacological treatment of CH with a focus on the mode of action of these drugs. We also summarized the clinical trial evidence and discuss future research directions.Recommendations for current pharmacological CH therapies, in particular for CH prevention, are often based on small open label studies with inconclusive results. Larger trials are missing. A shared pathophysiological mechanism of action of these preventatives does not exist. Future studies with CGRP(R) antibodies and novel substances with specific actions are needed and will thereby help to understanding the pathophysiology of CH. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|